Diphtheria, Tetanus, and H. Influenzae b Antibodies, IgG
Also known as: DTH
Use
This test is used to evaluate the ability of a patient to produce antibodies to pure protein vaccines (diphtheria and tetanus) and protein conjugated bacterial (H. influenzae) vaccines after vaccination. It helps rule out antibody deficiency by assessing the protective status of the antibodies against these diseases.
Special Instructions
Parallel testing of acute and convalescent specimens is preferred, and convalescent specimens must be received within 30 days from receipt of the acute specimens. Specimens should be clearly marked as 'Pre-Vaccine' or 'Post-Vaccine.'
Limitations
The test has not been cleared or approved by the US Food and Drug Administration. The performance characteristics were determined by ARUP Laboratories and the test is intended for clinical purposes. Accurate assessment might be difficult if the pre-vaccination concentration is greater than 1.0 IU/mL, as the response based on a ratio alone may not be sufficient.
New York Approved
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
LOINC Codes
- 13227-4
- 53935-3
- 11256-5
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1.5 mL
Minimum Volume
0.45 mL
Container
Serum separator tube or red tube
Collection Instructions
Transfer 1.5 mL serum to an ARUP standard transport tube.
Storage Instructions
Refrigerated
Causes for Rejection
Plasma or other body fluids. Contaminated, hemolyzed, or severely lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 year |